Substrates and inhibitors of chromatin-modifying enzymes are generated in intermediary metabolism, so changes in nutrient availability and utilization can influence epigenetic regulation 1,2 . Importantly, recent studies have indicated that the interplay between metabolism and epigenetics can serve as a programmed switch in cell states. For example, mouse embryonic stem cell differentiation is promoted by succinate-mediated inhibition of histone demethylases (HDMs) and TET DNA demethylases 3 , or by decreased S-adenosyl-methionine (SAM) levels leading to loss of histone H3K4 methylation 4 . Moreover, aberrant metabolic activity can produce pathological effects by altering chromatin regulation. Most notably, mutations in the genes encoding the isocitrate dehydrogenase (IDH)1 and IDH2 enzymes lead to the generation of 2-hydroxyglutarate, which inhibits HDMs and TETs and thereby alters DNA and histone methylation-changes that have been implicated in overriding cell differentiation and promoting tumorigenesis 5 . Whether this paradigm extends more generally to other oncogenic mutations remains unclear, and this question has implications for understanding cancer pathogenesis and developing improved treatments. Here, we demonstrate that dynamic exchange between metabolism and chromatin regulation contributes to pancreatic tumorigenesis driven by mutation of the LKB1 serine-threonine kinase.
Substrates and inhibitors of chromatin-modifying enzymes are generated in intermediary metabolism, so changes in nutrient availability and utilization can influence epigenetic regulation 1, 2 . Importantly, recent studies have indicated that the interplay between metabolism and epigenetics can serve as a programmed switch in cell states. For example, mouse embryonic stem cell differentiation is promoted by succinate-mediated inhibition of histone demethylases (HDMs) and TET DNA demethylases 3 , or by decreased S-adenosyl-methionine (SAM) levels leading to loss of histone H3K4 methylation 4 . Moreover, aberrant metabolic activity can produce pathological effects by altering chromatin regulation. Most notably, mutations in the genes encoding the isocitrate dehydrogenase (IDH)1 and IDH2 enzymes lead to the generation of 2-hydroxyglutarate, which inhibits HDMs and TETs and thereby alters DNA and histone methylation-changes that have been implicated in overriding cell differentiation and promoting tumorigenesis 5 . Whether this paradigm extends more generally to other oncogenic mutations remains unclear, and this question has implications for understanding cancer pathogenesis and developing improved treatments. Here, we demonstrate that dynamic exchange between metabolism and chromatin regulation contributes to pancreatic tumorigenesis driven by mutation of the LKB1 serine-threonine kinase.
LKB1 is mutationally inactivated in a range of sporadic cancers, including pancreatic carcinomas [6] [7] [8] . Additionally, germline mutations in LKB1 cause Peutz-Jeghers syndrome, which comprises gastrointestinal polyps and a high incidence of gastrointestinal tract carcinomas (for example, an approximately 100-fold increase in pancreatic cancer) 9, 10 . Cancers with LKB1 mutations tend to exhibit aggressive clinical features and different therapeutic sensitivity from cancers without these mutations [11] [12] [13] [14] . LKB1 directly activates a family of 14 kinases related to AMP-activated protein kinase (AMPK), many of which are coupled to nutrient sensing and broadly reprogram cell metabolism 15 . Thus, metabolic rewiring is thought to be a driver of tumorigenesis after LKB1 loss. We now identify an LKB1-regulated program that links metabolic alterations to control of the epigenome and is involved in malignant growth. Our results provide evidence that coupled metabolic and epigenetic states have a more general role in cancer pathogenesis and suggest therapeutic strategies that could target these intersecting processes.
Synergy between LKB1 and KRAS mutations
LKB1 inactivation frequently coincides with mutations in the RAS-RAF pathway in human cancers and these genetic alterations cooperate to drive tumorigenesis in genetically engineered mouse models (GEMMs) 6, 11, 14, 16 . We examined the interactions between oncogenic KRAS G12D and deletion of LKB1 in adult pancreatic ducts using a tamoxifen-inducible GEMM (Extended Data Fig. 1a) . The combined alterations resulted in pancreatic cancers by 20-25 weeks, whereas the individual mutations had no pathological effects at this age ( Fig. 1a and Extended Data Fig. 1b) Fig. 1d-g ). In vitro, KL cells showed greater proliferation than K cells, and both showed greater proliferation than wild-type or L cells (Extended Data Fig. 1h-j) . Thus, primary ductal cells provide a tractable in vitro system to study mechanisms of epithelial cell transformation arising from LKB1 inactivation. Focusing on the metabolic alterations provoked by loss of LKB1, we found that KL cells exhibited an approximately 30% increase in glucose uptake compared to K cells, and showed marked elevations in levels of the GLUT1 transporter and ATP ( Fig. 1c and Extended Data Fig. 1k, l) . Lactate levels were elevated in KL cells, whereas oxygen consumption and citrate levels were reduced (Fig. 1d , e and Extended Data Fig. 1m ). Moreover, KL cells showed heightened sensitivity to acute glucose deprivation and to inhibition of glycolysis using the glucose analogue 2-deoxyglucose, the pyruvate dehydrogenase kinase inhibitor dichloroacetate, or the lactate dehydrogenase inhibitor galloflavin (Extended Data Fig. 1n-q) . Importantly, neither KRAS G12D nor LKB1 inactivation alone promoted significant alterations in glucose metabolism (Extended Data Fig. 1r-t) . Thus, these genetic lesions acted synergistically to potentiate glycolysis while rendering cells highly dependent on glucose availability.
These data suggested that an increased supply of glycolytic intermediates was available for anabolic processes to support the growth of KL cells (Fig. 1f) . Notably, gene set enrichment analysis (GSEA) of RNA-sequencing (RNA-seq) and quantitative proteomics 17 data indicated that KL cells are enriched for glycolytic enzymes and for networks that connect glycolytic intermediates to one-carbon metabolism, with serine-glycine-threonine and folate metabolism scoring highly among the induced pathways (Supplementary Data Table 1 ). There was particularly striking enrichment of a 64-gene signature defining the entire serine-glycine-one carbon (SGOC) network 18 , indicating strong coordinate activation of these pathways ( Fig. 1g and Extended Data Fig. 2a) . Accordingly, the use of uniformly carbon-13-labelled glucose (U[ 
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pronounced increase in serine and glycine biosynthesis rates without changes in total levels of these amino acids ( 
Serine pathway dependence of KL cells
Multiple serine pathway enzymes (PSAT1, PSPH, SHMT1 and SHMT2) were upregulated in KL cells, whereas restoration of LKB1 expression reversed these changes, broadly suppressed the entire SGOC network, and reduced serine biosynthesis (Fig. 2a, b and Extended Data Fig. 2e-g ). PSAT1 catalyses the transamination of 3-phosphohydroxy-pyruvate (3PHP) to 3-phosphoserine (3PS), with glutamate as the nitrogen donor and α -ketoglutarate (α -KG) as a secondary product (Fig. 2a) . Consistent with elevated PSAT1 activity, [
15 N]glutamine labelling revealed a marked increase in nitrogen incorporation into serine and glycine in KL cells (Fig. 2c) . Thus, LKB1 restricts serine metabolism.
Consistent with this finding, KL cells were unaffected by culturing in serine-free medium, whereas K cells showed a roughly 40% decrease in proliferation, as did KL cells in which LKB1 was expressed ( Fig. 2d and Extended Data Fig. 3a) . On the other hand, KL cells were specifically sensitive to PSAT1 knockdown, exhibiting reduced proliferation in normal medium, restored dependency on exogenous serine, and impaired colony formation in soft agar ( Fig. 2e and Extended Data Fig. 3b-d) . Introduction of short hairpin (sh)RNA-resistant human PSAT1 cDNA rescued these phenotypes ( Fig. 2f and Extended Data Fig. 3e ). Moreover, PSAT1 knockdown strongly inhibited subcutaneous tumour growth by KL cells (Fig. 2g, h and Extended Data Fig. 3f, g ). Notably, PSAT1 knockdown had no effect on the proliferation or tumorigenicity of cell lines from pancreatic cancer GEMMs with wildtype LKB1 (KRAS G12D -p53 null, KPC and KRAS G12D -CDKN2A null, KIC) 19 , supporting the idea that these effects result from LKB1 loss rather than being secondary to high proliferation rates (Extended Data  Fig. 3b, h-k) . Thus, increased serine biosynthesis pathway activity is required to drive oncogenic transformation in KL cells.
Serine biosynthesis fuels DNA methylation
The serine biosynthesis pathway can fuel a range of anabolic processes, including generation of N 5 ,N 10 -methylene-tetrahydrofolate (THF), which supports NADPH production, redox homeostasis, and nucleotide biosynthesis 20 . PSAT1 knockdown failed to increase levels of reactive oxygen species (ROS) in KL cells and, correspondingly, proliferation was not restored by the ROS scavenger N-acetylcysteine (NAC) or by nucleoside supplementation (Extended Data Fig. 4a-d) .
Similar results were obtained after treatment with aminooxyacetate (AOA), an inhibitor of PSAT1 and other aminotransferases (Extended Data Fig. 4e, f) . Thus, the requirement of KL cells for PSAT1 appears to be independent of its roles in redox homeostasis or maintenance of nucleoside pools.
Serine metabolism can also fuel the methionine salvage pathway (Fig. 3a) , which is the main mechanism of production for the methyl donor S-adenosyl methionine (SAM) 21, 22 . Notably, multiple enzymes that channel serine metabolism intermediates into the methionine salvage pathway and that contribute to SAM biosynthesis were upregulated in KL cells (Extended Fig. 4g ). Accordingly, PSAT1 knockdown reduced SAM levels in KL cells but not in K cells (Fig. 3b) . Furthermore, SAM supplementation mitigated the proliferation defects caused by PSAT1 ablation in KL cells (Fig. 3c) . Conversely, suppression of SAM biosynthesis by inhibition of S-adenosyl-homocysteine-hydrolase (SAH) with 3-deazaadenosine (3DZA), or of methionine-adenosyltransferase (MAT) with cycloleucine, slowed the growth of KL cells, whereas K cells remained unaffected (Fig. 3d and Extended Data Fig. 4h) . Thus, activation of de novo serine biosynthesis contributes to SAM production to support growth of LKB1-deficient cells, possibly by providing active methyl groups in the form of N 5 -methyl-THF, or by promoting ATP generation (for example, via PSAT1-dependent TCA cycle anaplerosis) 22, 23 . SAM is the substrate for methylation of lipids, DNA, RNA, metabolites and proteins. Examination of our RNA-seq and proteomics data sets for the expression of the 183 annotated SAM-dependent methyltransferase enzymes revealed significant upregulation of the DNA methyltransferases DNMT1 and DNMT3A in KL cells, whereas few of the other enzymes showed any changes (Fig. 3e, Extended Data  Fig. 5a and Supplementary Data Table 2 ). Quantitative PCR and immunoblot analyses verified the regulation of expression of these enzymes by LKB1 (Extended Data Fig. 5b, c) . Importantly, inhibition of DNA methylation using 5-aza-2-deoxycytidine (decitabine) or the nonnucleoside DNMT inhibitor RG108 promoted SAM accumulation in KL cells but not in K cells (Extended Data Fig. 5d ), suggesting that DNMTs are major SAM-utilizing enzymes in the context of LKB1 deficiency.
Accordingly, immunofluorescence and DNA dot blot analysis demonstrated that KL cells had a significant increase in 5-methylcytosine (5mC) as compared to K cells, an effect that was reversed by LKB1 rescue (Extended Data Fig. 5e-g ). By contrast, there were no consistent changes in global levels of a series of histone methylation marks, in 5-hydroxy-methylcytosine, or in N 6 -methyladenosine (Extended Data  Fig. 5h-i and data not shown) . Notably, PSAT1 knockdown suppressed 
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DNA methylation in KL cells, and this effect was reversed by shRNAresistant PSAT1 cDNA, while K and KPC controls were unaffected. (Fig. 3f and Extended Data Fig. 6a-c) . Comparison of all four genotypes using our set of isogenic ductal cells confirmed that serine pathway activity and DNA methylation were specifically potentiated upon dual KRAS G12D expression and LKB1 loss (Extended Data Fig. 6d-g ). The expression of a kinase-dead (KD) LKB1 mutant confirmed that the activation of key transcriptional and metabolic circuits in KL cells was due to loss of LKB1 kinase activity (Extended Data Fig. 7a-e) . Accordingly, KL cells showed reduced activity of AMPK, an important target of the LKB1 kinase, and consequent activation of mechanistic target of rapamycin complex I (mTORC1) (Extended Data Fig. 7f, w) . Moreover, in K cells, AMPK suppression using the small molecule inhibitor dorsomorphin (compound C) or shRNAs targeting AMPKα 1 or AMPKα 2 increased each of the metabolic and gene expression parameters and upregulated global DNA methylation levels, mimicking the effects of LKB1 loss (Extended Data Fig. 7g-q) . Additionally, AMPK silencing blocked the effects of LKB1 re-expression on the growth and metabolic properties of KL cells (Extended Data Fig. 7r-u) . Finally, KL cells were hypersensitive to mTOR inhibition using Torin 1, which suppressed the metabolic and transcriptional changes seen in these cells (Extended Data Fig. 7v-z) . Thus, deregulation of AMPKmTORC1 signalling contributes to the altered metabolic and epigenetic network in KL cells.
LKB1 loss silences retrotransposons
DNA methylation can contribute to transcriptional regulation and maintenance of genomic stability 24 . We mapped methylation changes by conducting whole-genome bisulphite sequencing (WGBS) of K and KL cells (two independently derived lines per genotype). The data demonstrated a marked increase in mean CpG methylation in KL cells (Fig. 4a and Extended Data Fig. 8a) . Comparison of methylation levels at non-repetitive 100-bp tiles revealed 3,395 hypermethylated and 1,270 hypomethylated regions in KL cells (FDR < 0.05, methylation difference > 0.1; Fig. 4b and Extended Data Fig. 8b) . However, the genes associated with differentially methylated regions had only modest overlap with those showing differential expression, suggesting that methylation of these elements may not prominently affect transcriptional regulation (Extended Data Fig. 8c) . Thus, we focused on the repetitive portion of the genome. Notably, methylation in KL cells was particularly enriched at retrotransposon repeats (long terminal repeats (LTRs), long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs)) compared to non-repeat elements (promoters, CpG islands and shores) (Fig. 4c, d and Extended Data Fig. 8d-k) . These elements comprise a large proportion of the genome, have promoters that can be actively transcribed when unmethylated, and can influence regulation of host genes 25 . Consistent with a functional role for the observed retrotransposon methylation, KL cells had a > 50% reduction in LINE-1 expression compared to K cells (Fig. 4e) . Moreover, restoration of LKB1 suppressed LINE-1 methylation, as determined by 5mC-DNA immunoprecipitation-PCR analysis (meDIP-qPCR), and led to an approximately twofold upregulation of LINE-1 transcript expression (Fig. 4f, g ). Importantly, PSAT1 knockdown also reduced LINE-1 methylation and induced its expression in KL cells (Fig. 4h, i) , indicating that increased serine metabolism supports retrotransposon methylation and transcriptional silencing downstream of LKB1 loss.
Because retrotransposons can function as important modulators of host gene expression 25 , we explored the correlation between differentially expressed genes in K versus KL cells and the presence of linked retrotransposons. Retrotransposon elements were significantly enriched (χ 2 test, P < 0.0001) in the gene bodies of differentially expressed genes as compared to the distribution of these elements across all genes (Extended Data Fig. 8l, m) . By contrast, minimal enrichment was observed when promoter regions were considered. Such specificity is notable in light of evidence that intragenic methylation (including repeat methylation) can modify the activity of linked promoters and affect RNA processing 25, 26 . Thus, the LKB1-SGOC pathway alters the epigenetic landscape and dynamically regulates retrotransposon methylation and transcriptional activity, changes that appear to be associated with differences in host gene transcription.
KL cells are sensitive to DNMT inhibition
Consistent with the functional relevance of increased DNA methylation, KL cells were sensitive to shRNA-mediated knockdown of DNMT1 or DNMT3A, whereas K or KPC cells remained largely unaffected (Extended Data Fig. 9a-c) . Similar specific sensitivity of KL cells was observed in vivo using doxcycline (dox)-inducible shRNAs to acutely deplete DNMT1 or DNMT3 (or shGFP control) once subcutaneous tumours reached 50 mm 3 in size (Fig. 5a-c and Extended Data Fig. 9d-f) . These data indicate that inhibition of DNA methylation is a potential vulnerability of KL cells. Indeed, KL cells were hypersensitive assessed for methylation of LINE1 and 18S (f; n = 6, LINE1-1 and 18S; n = 4, LINE1-2), and LINE1 expression (g; n = 6). h, i, KL cells transduced with the indicated shRNAs were assessed for LINE1 and 18S methylation (h; n = 6) and LINE1 expression (i; n = 10). Data pooled from two (f, h) or representative of two (e, g, i) experiments. Error bars: s.d. * P < 0.05, * * P < 0.01, * * * P < 0.001. ARTICLE RESEARCH to the clinically approved DNMT inhibitor decitabine, as compared to K and KPC cell lines (IC 50 KL: 2 nM; K: 138 nM; KPC: 258 nM) ( Fig. 5d and Extended Data Fig. 9g-i) . Similar results were obtained using additional DNMT inhibitors (RG108, EGCG and SGI1027; Extended Data Fig. 9j-m) . Importantly, decitabine treatment caused striking regression of subcutaneous KL tumours, associated with necrosis, hyalinization, replacement of tumour glands with fibrosis, decreased tumour cell proliferation, and pronounced apoptosis (Fig. 5e-g ). By contrast, KPC xenografts were unaffected by decitabine (Extended Data Fig. 9n-q) . Thus, LKB1 deficiency confers specific hypersensitivity to inhibition of DNA methylation in vitro and in vivo.
Available human LKB1 mutant pancreatic cancer cell lines (COLO357 and SNU324) showed similar vulnerabilities. They exhibited 70-90% inhibition of proliferation following PSAT1 knockdown, whereas a set of LKB1 wild-type pancreatic cancer lines showed modest responses (Extended Data Fig. 10a) , consistent with prior results 27 in LKB1 wild-type lines. PSAT1 inactivation also inhibited the growth of LKB1 mutant COLO357 xenografts but not LKB1 wild-type MIAPACA2 xenografts (Extended Data Fig. 10b) . Moreover, LKB1 restoration or PSAT1 silencing decreased global methylation in COLO357 cells but not in PANC1 or PATU-8988T cells (Extended Data  Fig. 10c, d ). LKB1 mutant lines also exhibited an increased response to decitabine in vitro and in vivo, and to the methionine salvage pathway inhibitors 3DZA and cycloleucine (Fig. 5h, i and Extended Data  Fig. 10e) . Thus, both mouse and human LKB1 mutant pancreatic tumour cells are sensitized to inhibition of the serine pathway and to DNMT inhibition.
Discussion
In summary, we have defined a metabolic state central to tumorigenesis resulting from LKB1 loss in which glucose and glutamine-derived intermediates are channelled towards the SGOC network leading to increased DNA methylation (Extended Data Fig. 10f ). Such interplay between metabolic control and epigenetic reprogramming has been proposed as a key mechanism for cancer development in the context of mutations in metabolic enzymes 1, 2, 5 . The present work provides evidence for a broader role of metabolic and epigenetic crosstalk in cancer pathogenesis, revealing that LKB1 mutant pancreatic cancer cells have a marked dependency on pathways linking glycolysis, serine metabolism and DNA methylation.
It appears probable that the influence of aberrant metabolism on epigenetics contributes to cancer in the context of other oncogenic mutations. For instance, PI3K/AKT signalling controls acetyl-coenzyme A metabolism to support histone acetylation and regulate growthpromoting genes 28 . Numerous oncogenic pathways rewire metabolism, and the circuits that are activated vary widely, with different genetic lesions favouring distinct fates of glucose, glutamine, fatty acids, and other nutrients. Thus, the resulting alterations in the levels of metabolites affecting chromatin regulation (for example, NAD + /NADH, FAD, O-linked N-acetylglucosamine, free fatty acids, SAM and acetyl-CoA) may be fundamental to cancer-promotion. Varying conditions in the tumour microenvironment may alter tumour phenotypes via similar processes 29, 30 . The gain in DNA methylation at retrotransposons that we observed in KL cells is notable in light of the emerging view that these abundant repeat elements serve critical roles in host gene regulation 25 . Moreover, there is increasing evidence that reactivation of silenced retrotransposons may underlie the therapeutic benefit of DNMT inhibitors, serving to induce a type I interferon anti-viral defence program 31, 32 . The basis for the widespread differences in response to DNMT inhibitors observed in vitro and in the clinic remains unclear. In this regard, our studies in KRAS mutant pancreatic ductal cells suggest that LKB1 status is a 
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genetic marker for DNMT inhibitor responsiveness. Because repeat element methylation does not strictly correlate with sensitivity to these treatments 33 , the precise mechanisms of the specific response of KL cells to DNMT inhibitors remain to be defined. In this setting, it will be of interest to determine the relative contributions of IFN pathway activation and of modulation of host gene expression. Together, our data point to novel therapeutic vulnerabilities in the context of LKB1 mutations, suggesting that it might be possible to use agents targeting nodes of this network in defined patient subsets, although additional studies will be needed to broadly establish these associations in human cancers.
Our findings and other recent reports highlight the importance in cancer of the deregulation of serine biosynthesis, which can result from amplification of genes encoding pathway enzymes 23, 34 or their transcriptional activation downstream of oncogenic drivers, including NRF2 35 , c-MYC [36] [37] [38] , and mTOR 39 . Serine metabolism can fuel diverse biosynthetic pathways and contribute to energy production. Correspondingly, its functional role in aberrant growth appears context dependent, relating variously to supporting nucleotide biosynthesis, NADPH production, TCA cycle anaplerosis, and DNA or histone methylation. These findings underscore the emerging interest in developing new approaches to targeting components of the SGOC network as cancer therapeutics.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. shPSAT1-1, or shPSAT1-2. Note that PSAT1 knockdown tumours have a reduction in malignant glands (arrows) relative to the fibrotic stroma. Lower panels: anti-CK19 (green) was used to visualize the neoplastic epithelium and anti-PCNA (red) was used to mark proliferation. DAPI was used to stain nuclei (blue). h, Proliferation of KPC and KIC pancreatic cancer cells transduced with shControl or two independent shRNAs against PSAT1. Growth is expressed as relative to day 0 (n = 6 for KPC and n = 4 for KIC). i-k, KPC cells were transduced with shControl (n = 6), shPSAT1-1 (n = 6) or shSPAT1-2 (n = 4) and injected into SCID mice. i, Volume (left) and weight (right) of subcutaneous tumours. Error bars show s.e.m. For source data on tumour volume, see Supplementary Data Table 4 . j, k, Tumours in i were stained using anti-CK19 antibody (green) to visualize the neoplastic epithelium and anti-PCNA staining (red) to mark proliferating cells. DAPI was used to stain nuclei (blue). The proportion of stained CK19
+ cells is quantified in j (n = 4, representative tumours) and CK19
+ cells with nuclear PCNA staining are quantified in j. There are no significant effects on any of these parameters. k, Haematoxylin and eosin-stained sections (top) and immunofluorescence analysis (bottom) of representative tumours. Scale bars, 100 μ m. Insets show threefold magnification. Data pooled from two (c, d) or representative of two (a, b, e) or three (h) experiments. For all panels, error bars show s.d. unless otherwise stated; * P < 0.05, * * P < 0.01, * * * P < 0.001.
